{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:31:57Z","timestamp":1777883517729,"version":"3.51.4"},"reference-count":55,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005258","name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention","doi-asserted-by":"publisher","award":["6 NU62PS005094-01"],"award-info":[{"award-number":["6 NU62PS005094-01"]}],"id":[{"id":"10.13039\/100005258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp;amp; Addiction Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Injection drug use (IDU) is a risk factor for hepatitis C virus (HCV) acquisition and occurs disproportionately among women who exchange sex (WES). However, little is known about HCV epidemiology in this population. We estimated HCV seroprevalence, identified correlates of HCV seropositivity, and characterized social networks by HCV serostatus and IDU history among WES in the Seattle, Washington, area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a secondary analysis of data from the 2016 National HIV Behavioral Surveillance survey in the Seattle, Washington area, a cross-sectional survey that used respondent-driven sampling (RDS) to enroll WES for money or drugs (N\u2009=\u2009291). All participants were offered rapid HCV-antibody testing. We estimated HCV seropositivity and used log regression methods to estimate crude and adjusted prevalence ratios (PRs) for correlates of HCV seropositivity among WES. Using RDS recruitment chain data, we computed homophily indices to estimate the extent to which participants were likely to recruit another participant with the same HCV serostatus and IDU history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the study sample of WES in the Seattle, Washington area, 79% reported lifetime IDU and 60% were HCV seropositive. HCV seropositivity was strongly associated with ever injecting drugs (PR\n                      <jats:sub>adj<\/jats:sub>\n                      : 7.7 [3.3, 18.0]). The RDS homophily scores for HCV seropositivity (0.07) and ever injecting drugs (0.02) suggested that participants did not tend to recruit others with the same characteristics beyond what would be expected by chance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Among this sample of WES in Seattle, Washington area, HCV seroprevalence was high and strongly associated with a history of IDU. The high burden of HCV among WES suggests this marginalized group would benefit from additional harm reduction services and targeted HCV treatment campaigns to reduce forward transmission. We saw little evidence of preferential recruitment among WES who were HCV seropositive or reported a history of IDU, suggesting the potential futility of peer-based referrals for HCV treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342231208936","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T05:08:09Z","timestamp":1703826489000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["High Seroprevalence of Hepatitis C Virus Among Cisgender Women Who Exchange Sex in the Seattle, Washington Area"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4878-1208","authenticated-orcid":false,"given":"Michael P.","family":"Barry","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"name":"HIV\/STD Program, Public Health\u2014Seattle & King County, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Corcorran","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Moreno","sequence":"additional","affiliation":[{"name":"HIV\/STD Program, Public Health\u2014Seattle & King County, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Buskin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"name":"HIV\/STD Program, Public Health\u2014Seattle & King County, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon L.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"name":"Department of Global Health, University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara N.","family":"Glick","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle, WA, USA"},{"name":"HIV\/STD Program, Public Health\u2014Seattle & King County, Seattle, WA, USA"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"bibr1-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.10.019"},{"key":"bibr2-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.01.026"},{"key":"bibr3-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.04.017"},{"key":"bibr4-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00477-5"},{"key":"bibr5-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.12.019"},{"key":"bibr6-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2561-0"},{"key":"bibr7-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13194"},{"key":"bibr8-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-017-0184-8"},{"key":"bibr9-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jtg137"},{"key":"bibr10-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108525"},{"key":"bibr11-29767342231208936","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305366"},{"key":"bibr12-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa112"},{"key":"bibr13-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515195"},{"key":"bibr14-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02680-9"},{"key":"bibr15-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.05.039"},{"key":"bibr16-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1739204"},{"key":"bibr17-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2023.01.005"},{"key":"bibr18-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25352"},{"key":"bibr19-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1177\/2040622314551934"},{"key":"bibr20-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.024"},{"key":"bibr21-29767342231208936","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1876"},{"key":"bibr22-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5148"},{"key":"bibr23-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108135"},{"key":"bibr24-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz452"},{"key":"bibr25-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102755"},{"key":"bibr26-29767342231208936","doi-asserted-by":"publisher","DOI":"10.2307\/3096941"},{"key":"bibr27-29767342231208936","unstructured":"R Studio Team. RStudio: integrated development for R. 2020. Accessed November 10, 2021. http:\/\/www.rstudio.com\/"},{"key":"bibr28-29767342231208936","unstructured":"Stevenson M, Nunes T, Sanchez J, et al. EpiR: an R package for the analysis of epidemiological data. 2021. Accessed November 10, 2021. https:\/\/fvas.unimelb.edu.au\/research\/groups\/veterinary-epidemiology-melbourne"},{"key":"bibr29-29767342231208936","unstructured":"US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Social determinants of health. Healthy People 2030. 2020. Accessed February 8, 2021. https:\/\/health.gov\/healthypeople\/priority-areas\/social-determinants-health"},{"key":"bibr30-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi188"},{"key":"bibr31-29767342231208936","volume-title":"Respondent-Driven Sampling Analysis Tool (RDSAT)","author":"Volz E"},{"key":"bibr32-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1525\/sp.2002.49.1.11"},{"key":"bibr33-29767342231208936","unstructured":"Handcock M, Fellows I, Gile K. RDS analyst: software for the analysis of respondent-driven sampling data. 2014. Accessed November 10, 2021. Hpmrg.org"},{"key":"bibr34-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9531.2007.00188.x"},{"key":"bibr35-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.04.037"},{"key":"bibr36-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13735"},{"key":"bibr37-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108527"},{"key":"bibr38-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-07581-7"},{"key":"bibr39-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108684"},{"key":"bibr40-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.07.007"},{"key":"bibr41-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0313"},{"key":"bibr42-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz294"},{"key":"bibr43-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001064"},{"key":"bibr44-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00260-8"},{"key":"bibr45-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103924"},{"key":"bibr46-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000261107"},{"key":"bibr47-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e31823ac17c"},{"key":"bibr48-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-013-0451-y"},{"key":"bibr49-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1086\/592171"},{"key":"bibr50-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"bibr51-29767342231208936","unstructured":"Centers for Disease Control and Prevention. Division of viral hepatitis 2025 strategic plan. 2020. Accessed March 27, 2023. https:\/\/www.cdc.gov\/hepatitis\/pdfs\/DVH-StrategicPlan2020-2025.pdf"},{"key":"bibr52-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.11.026"},{"key":"bibr53-29767342231208936","unstructured":"State of HepC. 2023 hep C: state of medicaid access report cards are in. 2023. Accessed August 17, 2023. https:\/\/stateofhepc.org\/2023-hep-c-state-of-medicaid-access-report-cards-are-in\/"},{"key":"bibr54-29767342231208936","unstructured":"Washington State Department of Health, Washington State Healthcare Authority. Urgent: test and treat people who use drugs for hepatitis C. 2021. Accessed August 17, 2023. https:\/\/doh.wa.gov\/sites\/default\/files\/legacy\/Documents\/Pubs\/\/150-146-HepC-cliniciantestingbrief.pdf"},{"key":"bibr55-29767342231208936","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.2291"}],"container-title":["Substance Use &amp;amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231208936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342231208936","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231208936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:48:50Z","timestamp":1777600130000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/29767342231208936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/29767342231208936"],"URL":"https:\/\/doi.org\/10.1177\/29767342231208936","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}